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Wald et al Evolving Technology/Basic Scienceto the circulation. Furthermore, distant sites where CXCL12
is highly expressed may serve as favorable niches for metas-
tasis to occur. At these locations, a paracrine CXCL12/
CXCR4 loop may stimulate tumor cell proliferation and
induce extracellular matrix rearrangement, necessary for
metastasis formation.
Finally, we showed that CXCL12 stimulation resulted in
production of the proinflammatory chemokine CCL20 by
neoplastic cells. This may explain our previous observation
that CXCL12 expression in lung adenocarcinoma was asso-
ciated with increased tumor inflammatory load and the ac-
cumulation and retention of CD4þ T cells.3 In addition to
CD4þT cells, immature dendritic cells were also shown to
accumulate in NSCLC.2 The trafficking of such cells is gov-
erned in part by both CXCL12 and CCL20.2,5 Dumitriu and
colleagues29 recently described the potential of dendritic
cells to induce differentiation of FoxP3 regulatory T cells
on exposure to NSCLC cells.29 Thus augmentation of tumor
inflammation and recruitment of tumor promoting rather
than suppression of immune cells may be an additional
mechanism by which the CXCL12/CXCR4 axis promotes
NSCLC growth and spread.
In conclusion, our findings suggest that the interaction of
CAFs and tumor neoplastic cells and the CXCL12/CXCR4
axis play a role in tumor cell proliferation, thus marking
CXCL12/CXCR4 axis as a target for immune intervention
in the treatment of NSCLC.E
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Dr Steven J. Mentzer (Boston, Mass). Thank you, Dr Wald.
That was a nice presentation, and your written article was equally
thoughtfully put together.
For those of us who sometimes blur when we think about chemo-
kines—and I think there are now roughly 44 or 45 chemokines
known, so I think often people tune out—there are a few that are
very important to thoracic surgeons. CCL2, or the old MCP-1,
seems to be involved in a lot of different lung diseases, and
CXCR4 is very important in terms of human cancer. I think it has
been demonstrated in more than 20 human cancers. One of the
things that I think is interesting about your study is the heterogeneitydiovascular Surgery c Volume 141, Number 6 1511
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Sin the samples that you showed, at least in the written article. Did
you look at metastatic disease? If you imagine a subpopulation
and if, for example, CXCR4 expression were important, you would
perhaps expect that to be selected for in metastatic disease. Did you
have an opportunity to look at that in any metastatic lesions?
Dr Wald. Well, we have conducted 2 studies focusing mainly
on CXCL12, because some data regarding the expression of
CXCR4 had already been published. In 2 different series, 1 that
we reported in the past and 1 that we have now, we found some cor-
relation between the level of CXCL12 expression and recurrence
of disease. I assume that the balance of expression between the
chemokine and the receptor will determine the outcome in many
patterns. If you have expression of both the chemokine and the re-
ceptor in the tumor microenvironment, you might think that an au-
tocrine loop or a paracrine loop is actually acting and may support
tumor growth locally, whereas if you have, for example, expres-
sion of the chemokine on vascular structures and fibroblasts at
the tumor edge or border with expression of the chemokine itself
by the tumor cells, then this pattern might favor the possibility
of guiding tumor metastatic spread. I think, however, that this is
something that would be difficult to prove.
Dr Mentzer. One of the problems with a lot of chemokine re-
search is that people kind of reach too far. They try to overinterpret
their data. The CXCL12, it’s actually stromal cell–derived factor 1
(SDF-1); it stops lymphocytes on a dime, it recruits endothelial
progenitor cells, and it is expressed in a lot of tumors. It does
a lot of different things. I don’t think you have to try to explain
it in in vitro work. And particularly the problem with in vitro
work is that the cells are responding to polystyrene, not to the tu-
mor microenvironment, which I think is a practical problem.
I think back to 8 or 10 years ago, when this was first discov-
ered in breast cancer metastatic disease, Dynex and a variety of1512 The Journal of Thoracic and Cardiovascular Surother companies were developing small-molecule inhibitors.
Can you envisage that kind of therapeutic potential in treating
lung cancer?
Dr Wald. Well, today there is 1 molecule that is already ap-
proved for clinical use, I think it is AMD3100 (Plerixafor). I think
that the method of delivery is highly important, because, as you
mentioned, the CXCL12/CXCR4 axis is important in many ho-
meostatic processes in the body. So if one wants to look at this
as a therapeutic target, one must look for a way to deliver the
drug specifically into the tumor, or at least use molecules that
have a short half-life, maybe that predispose the cells to the action
of other therapeutic agents, such as chemotherapy. I think this
might be the path.
Dr Mentzer. Nice work. Thank you.
Dr Nasser K. Altorki (New York, NY). I want to congratulate
you on pursuing this idea of crosstalk between the CAFs and the
tumor. This will be an area of great interest going forward.
I understood you to say that thesewere primary-derived cultures
from tumors, and I wondered whether you could share with us
some of the tricks that you used to develop epithelial cell lines, be-
cause in our hands the success rate is less than 10%.
Dr Wald. I’m afraid, as we wrote in the article, that our per-
centage of success is around 10%. I think that it’s very tough to
isolate the primary tumor cells. I know that other people in our
institution have tried to collect them from pleural effusions, and
they have a had a relatively high rate of success. What we have
done, and sometimes it seems promising, is initially grow the
cells on plates and then use like a colony assay and select specific
colonies. There are also kits available for that, which seemed to
be a bit more useful in some of the cases, but the success rate
is still low.
Dr Altorki. Thank you, and congratulations.gery c June 2011
